Job title: CTO
Steffen Walter joined Immatics Biotechnologies GmbH in 2005 where he became Director and Head of lmmunology Setup and administration of an R&D department.
For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities.
In 2015, Steffen Walter established operations of Immatics US, Inc. in Houston, Texas in close collaboration with MD Anderson Cancer Center (MDACC) as Chief Scientific Officer to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas.
Steffen Walter leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs.
Steffen Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Lancet Oncology, Brain and Blood.
Steffen Walter gained his Ph.D. in Immunology from the University of Tuebingen, Germany.
Live Q&A Discussion 5:50 pm
day: Day One
ACTallo®, an Off-the-Shelf Adoptive Cell Therapy Approach Using αβ TCR-transduced γδ T cells 5:30 pm
• We believe that γδ T cells are ideally suited for allogenic Adoptive Cell Therapy approaches because they naturally infiltrate tumors, possess intrinsic antitumor activity and recognize target cells in an HLA/peptide independent fashion, not causing Graft-versus-Host Disease • ACTallo® is a process developed by Immatics for the manufacture of allogeneic, offthe- shelf, TCR-engineered cellular…Read more
day: Day One